Dr Reddys Laboratories Ltd News

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Stocks to Watch today, Dec 15: Swiggy, BEL, Tata Elxsi, Aurobindo Pharma

Stocks to watch today, December 15, 2025: From Tata Elxsi to Aurobindo Pharma, here is a list of stocks to keep in focus

Larger HC Bench clears way for export of semaglutide generics by Dr Reddy's

Novo Nordisk's appeal was listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Dr Reddy's signs licensing pact with Immutep to develop, market cancer drug

According to the agreement, Immutep will receive from Dr Reddy's an upfront payment of $20 million (around AUD 30.2 million)

Dr Reddy's signs licensing pact to sell Australian Immutep's cancer drug

Over the last few years, Dr Reddy's has diversified its portfolio beyond generics to include cancer therapies as it battles pricing pressures in North America, its largest market

Rupee at record low, MPC caution drag Nifty; check strategy, stock picks

Sentiment was dampened by a weakening rupee, which hit a record low of 90.13 against the dollar, heightening concerns around import costs and triggering FII outflows

Nifty50 to hit 29,300 by end-2026? Nomura lists top 20 stock picks

Nomura expects Indian markets to trade in the range of 20-22x one-year forward earnings, assuming risk premia remain low.

Why did Dr Reddy's share rise over 2% in overall subdued market? Details

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Stocks to Watch today, Nov 25: Siemens Energy, Dr Reddy's, Cello, HUDCO

Stocks to Watch Today, November 25, 2025: Dr. Reddy's Labs, Siemens Energy, HUDCO, Sunteck Realty and other stocks will remain in focus; here's why

Policymakers-industry partnership vital for healthcare delivery: Dr Reddy's

Dr Reddy's Laboratories on Monday said partnerships between policymakers and industry are vital to build a future-ready healthcare system that serves millions. Satish Reddy, the chairman of the Hyderabad-based drug major, joined industry leaders at the sixth Pre-Budget Consultation chaired by Union Finance Minister Nirmala Sitharaman in the national capital. He shared his perspective on the importance of risk-based innovation funding to strengthen India's pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability. "At Dr Reddy's, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions," Reddy said in a post shared by the drug firm on social networking platform LinkedIn.

Dr Reddy's gets EU nod for drug used to treat bone-weakening conditions

The European Commission's approval allows Dr Reddy's to market AVT03 across the European Union and European Economic Area for treating conditions that cause bone weakening

Canada notice may delay Dr Reddy's semaglutide generic launch

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday

Dr Reddy's plunges 6%, hits 5-month low; why pharma stock under pressure?

Dr Reddy's Laboratories has received a Notice of Non-Compliance from Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission for Semaglutide Injection.

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Stocks to Watch today: RIL, Dr Reddy's Labs, Coforge, Hudco, Container Corp

Stocks to Watch Today, Monday, October 27, 2025: Reliance Industries, Container Corporation of India, PTC Industries, Mazagon Dock Shipbuilders, and Indian Oil are among the top stocks to watch today

Dr Reddy's Q2FY26 results: Profit up 14% at ₹1,437.2 cr, revenue jumps 10%

Dr Reddy's Ebitda for the quarter stood at ₹2,351.1 crore, up 3 per cent Y-o-Y and sequentially, with an Ebitda margin of 26.7 per cent

Q2 results today: Dr Reddy's Labs, ITC Hotels, NACL Industries on Oct 24

Aditya Birla Sun Life AMC, SBI Life Insurance Company, SBI Cards and Payment Services, India Radiators, and Sigachi Industries will also release their September quarter earnings reports today

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

USFDA says 'voluntary action' required at Dr Reddy's Srikakulam unit

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulator for its formulations manufacturing facility at Srikakulam in Andhra Pradesh, classifying the facility as voluntary action indicated. The US Food & Drug Administration (USFDA) had conducted a GMP and a Pre-Approval Inspection (PAI) conducted by at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India, intimated to the exchanges on July 18, 2025, Dr Reddy's Laboratories Ltd said in a regulatory filing. "We wish to inform you that the company has received the Establishment Inspection Report (EIR) on October 20, 2025. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)'," it said, adding the inspection is officially closed. Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or ...